Tomi Jun

Tomi Jun

Auto-generated profile, based on publicly available information

Tomi Jun

Department of Medicine, Division of Hematology/Oncology, Tisch Cancer Institute, Mount Sinai Hospital, New York, NY 10029, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2020 in Blood
Verified
Journal Article
Open access
PDF file
DTDouglas Tremblay
Douglas Tremblay
Maaike van GerwenMaaike van Gerwen
Maaike van Gerwen
MAMathilda Alsen
Mathilda Alsen
STSantiago Thibaud
Santiago Thibaud
AKAlaina Kessler
Alaina Kessler
LNLeonard Naymagon
Leonard Naymagon
Tremblay and colleagues asked whether patients receiving either routine anticoagulation or antiplatelet therapy for existing conditions prior to becoming ill with COVID-19 have different outcomes from patients receiving neither therapy. After matching for existing comorbidities, this retrospective observational study finds no evidence for an effect of prediagnosis anticoagulation on mortality.

31 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMAmbreen Muhammed
Ambreen Muhammed
CFClaudia Fulgenzi
Claudia Fulgenzi
SDSirish Dharmapuri
Sirish Dharmapuri
MPMatthias Pinter
Matthias Pinter
LBLorenz Balcar
Lorenz Balcar
David James PinatoDavid James Pinato
David James Pinato
Systemic inflammation is a hallmark of cancer, and it has a pivotal role in hepatocellular carcinoma (HCC) development and progression. We conducted a retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence of neutrophiles to lymphocytes ratio (NLR), platelets to lymphocytes ratio (PLR), and prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), and radiologic responses. In our 362 patients treated with immunotherapy, median OS and PFS were 9 and 3.5 months, respectively. Amongst tested inflammatory biomarkers, patients with NLR ≥ 5 had shorter OS (7.7 vs. 17.6 months, p < 0.0001), PFS (2.1 vs. 3.8 months, p = 0.025), and lower objective response rate (ORR) (12% vs. 22%, p = 0.034); similarly, patients with PLR ≥ 300 reported shorter OS (6.4 vs. 16.5 months, p < 0.0001) and PFS (1.8 vs. 3.7 months, p = 0.0006). NLR emerged as independent prognostic factors for OS in univariate and multivariate analysis (HR 1.95, 95%CI 1.45–2.64, p < 0.001; HR 1.73, 95%CI 1.23–2.42, p = 0.002) and PLR remained an independent prognostic factor for both OS and PFS in multivariate analysis (HR 1.60, 95%CI 1.6–2.40, p = 0.020; HR 1.99, 95%CI 1.11–3.49, p = 0.021). Systemic inflammation measured by NLR and PLR is an independent negative prognostic factor in HCC patients undergoing ICI therapy. Further studies are required to understand the biological mechanisms underlying this association and to investigate the predictive significance of circulating inflammatory biomarkers in HCC patients treated with ICIs.

10 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
David James PinatoDavid James Pinato
David James Pinato
TKTakahiro Kaneko
Takahiro Kaneko
ASAnwaar Saeed
Anwaar Saeed
TPTiziana Pressiani
Tiziana Pressiani
AKAhmed Omar Kaseb
Ahmed Omar Kaseb
YHYi-Hsiang Huang
Yi-Hsiang Huang
Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI in HCC. We tested the accuracy of the albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker to the Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset of HCC patients, we assessed safety and efficacy of ICI across varying levels of liver dysfunction described by CTP (A to C) and ALBI grade and evaluated uni- and multi-variable predictors of overall (OS) and post-immunotherapy survival (PIOS). We studied 341 patients treated with programmed-death pathway inhibitors (n = 290, 85%). Pre-treatment ALBI independently predicted for OS, with median OS of 22.5, 9.6, and 4.6 months across grades (p < 0.001). ALBI was superior to CTP in predicting 90-days mortality with area under the curve values of 0.65 (95% CI 0.57–0.74) versus 0.63 (95% CI 0.54–0.72). ALBI grade at ICI cessation independently predicted for PIOS (p < 0.001). Following adjustment for ICI regimen, neither ALBI nor CTP predicted for overall response rates or treatment-emerging adverse events (p > 0.05). ALBI grade identifies a subset of patients with prolonged survival prior to and after ICI therapy, lending itself as an optimal stratifying biomarker to optimise sequencing of systemic therapies in advanced HCC.

8 October 2021 in Liver Cancer
Verified
Journal Article
Open access
PDF file
PFPetros Fessas
Petros Fessas
MNMuntaha Naeem
Muntaha Naeem
MPMatthias Pinter
Matthias Pinter
TMThomas U. Marron
Thomas U. Marron
DSDavid Szafron
David Szafron
David James PinatoDavid James Pinato
David James Pinato
Background and Rationale: Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI therapy can impact immunotherapy efficacy across indications; however, the effect of ATB is undefined in HCC. Methods: In a large international cohort of 450 ICI recipients from Europe, North America, and Asia, we categorized patients according to timing of ATB focusing on exposure within −30 to +30 days from ICI (early immunotherapy period [EIOP]). EIOP was evaluated in association with overall survival (OS), progression-free survival (PFS), and best radiologic response using RECIST 1.1 criteria. Results: Our study comprised mostly cirrhotic (329, 73.3%) males (355, 79.1%) with a Child-Turcotte Pugh class of A (332, 73.9%), receiving ICI after 1 therapy line (251, 55.9%) for HCC of Barcelona clinic liver cancer stage C (325, 72.4%). EIOP (n = 170, 37.9%) was independent of baseline clinicopathologic features of HCC and correlated with longer PFS (6.1 vs. 3.7 months, log-rank p = 0.0135). EIOP+ patients had similar OS, overall response, and disease control rates (DCRs) compared to EIOP. The effect of EIOP persisted in landmark time analyses and in multivariable models, confirming the independent predictive role of EIOP in influencing PFS following adjustment for covariates reflective of tumor burden, liver function, and ICI regimen administered. In patients receiving programmed cell death-1 receptor/ligand inhibitors monotherapy, EIOP was also associated with higher DCRs (61.4% vs. 50.9%, p = 0.0494). Conclusions: Unlike other oncological indications, ATB in the 30 days before or after ICI initiation is associated with improved benefit from immunotherapy, independent of disease and treatment-related features. Evaluation of the immune microbiologic determinants of response to ICI in HCC warrants further investigation.

1 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
David James PinatoDavid James Pinato
David James Pinato
TMthomas marron
thomas marron
PMPallavi Shruti Mishra-Kalyani
Pallavi Shruti Mishra-Kalyani
YGYutao Gong
Yutao Gong
GWGuo Wei
Guo Wei
LPLorraine Pelosof
Lorraine Pelosof

13 June 2016 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
RRR. Rajbhandari
R. Rajbhandari
TJT. Jun
T. Jun
HKH. Khalili
H. Khalili
RCRaymond T. Chung
Raymond T. Chung
AAA. N. Ananthakrishnan
A. N. Ananthakrishnan